WS06 – HLA desensitization

Despite a marked increase in the number of living-donor allografts (LDAs) transplanted annually, many potential recipients with otherwise suitable donors are relegated to the ever-expanding deceased-donor waiting list because of preformed human leukocyte antigen (HLA) antibodies. These are acquired via pregnancy, transfusion, and/or prior transplant.

The presence of these anti- HLA antibodies in the potential recipient’s blood is called HLA sensitization. If not adequately suppressed, the presence of such antibodies is likely to result in antibody- mediated rejection (ABMR) and early graft loss.

ABMR was recognized early in the history of transplantation as hyperacute rejection caused by the presence of preformed antibodies, most typically in the form of antibodies to donor HLAs. Introduction of pretransplant crossmatch techniques has essentially eliminated hyperacute rejection.

Target group: All members of the multi-disciplinary team involved in transplantation

Leader: Nizam Mamode

Group members: Oriol Bestard (Spain), Christophe Legendre (France), Maarten Naesens (Belgium), Lucrezia Furian (Italy), Sian Griffin (UK), Frans Claas (The Netherlands)

Forum moderator: Edoardo Melilli

Preliminary Activities:

TLJ 2.0 PREPARATORY WEBINAR SERIES: WS06 (Supported by Hansa) – Transplanting patients with HLA antibodies: who, when and how (18:00-19:00, 5 October, 2020)

Link to webinar

ESOT would greatly appreciate your participation in short survey, to support the development of guidelines to help clinical decisions in managing patients with HLA antibodies. Results of this survey will be collated from 28 October 2020.

Link to survey

 

kindly supported by an unrestricted grant from industry